Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M706078200 on August 15, 2007

J. Biol. Chem., Vol. 282, Issue 43, 31601-31609, October 26, 2007
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/43/31601    most recent
M706078200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vitovski, S.
Right arrow Articles by Croucher, P. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vitovski, S.
Right arrow Articles by Croucher, P. I.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Investigating the Interaction between Osteoprotegerin and Receptor Activator of NF-{kappa}B or Tumor Necrosis Factor-related Apoptosis-inducing Ligand

EVIDENCE FOR A PIVOTAL ROLE FOR OSTEOPROTEGERIN IN REGULATING TWO DISTINCT PATHWAYS*

Srdjan Vitovski, Jennifer S. Phillips, Jon Sayers, and Peter I. Croucher1

From the Academic Unit of Bone Biology, Section of Musculoskeletal Science and the Section of Infection, Inflammation and Immunity, University of Sheffield School of Medical and Biomedical Sciences, Beech Hill Road, Sheffield, Yorkshire S10 2RX, United Kingdom

Received for publication, July 24, 2007


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Osteoprotegerin (OPG) binds the ligand for receptor activator of nuclear factor {kappa}B (RANKL) to prevent association with its receptor RANK and inhibit osteoclast-mediated bone resorption. OPG has been reported, recently, to inhibit tumor necrosis factor-related apoptosis-induced ligand (TRAIL)-induced tumor cell apoptosis. This raises the possibility that OPG may play a unique role in regulating these two signaling pathways. However, there are little data on the interactions between OPG, RANKL, and TRAIL, and the relative affinity of OPG for these two ligands is unknown. In the present study we examined the ability of OPG to bind native human TRAIL and RANKL under physiological conditions. Native TRAIL was expressed in Escherichia coli, purified to homogeneity, and shown to induce human myeloma cell apoptosis. OPG inhibited native TRAIL from binding the TRAILR1 at 37 °C in vitro. Similarly, OPG prevented RANKL from binding to RANK. TRAIL also prevented OPG-mediated inhibition of RANKL from binding RANK. The affinity of OPG for native TRAIL and RANKL at 37 °C was determined by plasmon surface resonance analysis. OPG had a binding affinity for TRAIL of 45 nM, whereas the affinity of OPG for RANKL was 23 nM. These data suggest that OPG can bind both RANKL and TRAIL and that the affinity of OPG for these two ligands is of a similar order of magnitude. Furthermore, OPG prevented TRAIL-mediated reductions in cell viability, whereas TRAIL inhibited OPG-mediated inhibition of osteoclastogenesis in vitro. This highlights the pivotal role of OPG in regulating the biology of both RANKL and TRAIL.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Bone is a complex tissue that is constantly being replaced through the process of bone remodeling. This process is mediated by the removal of bone by osteoclasts and its subsequent replacement by osteoblasts. Disruptions to the normal, coupled, activity of these cell types leads to skeletal disorders. The activity of osteoclasts and osteoblasts is regulated by the concerted actions of specific messengers, including hormones, adhesion molecules, local growth factors, and cytokines. One family of cytokines that plays a central role in regulating osteoclast cell function is the tumor necrosis factor (TNF)2 superfamily (1). Although a number of TNF family members has been shown to regulate osteoclast formation and function, one system has been shown to play a central role. This is the osteoprotegerin (OPG)/ligand for receptor activator of NF{kappa}B (RANKL)/receptor activator of NF{kappa}B (RANK) pathway (2).

Osteoprotegerin was first identified through screening a fetal rat intestinal cDNA library, searching an expressed sequence tag data base, and by direct purification from the supernatant derived from human fibroblasts (3-5). Analysis of the protein sequence identified structural motifs that were similar to those seen in members of the TNF receptor family, and thus OPG was identified as a new member of the TNF receptor family (3, 6). However, OPG lacks a transmembrane domain and, unlike the majority of members of this family, is secreted into the extracellular space (7). Subsequently, a ligand for OPG was identified using an expression cloning strategy (8, 9). The ligand was shown to be identical to two previously described proteins that regulate dendritic cell and mature T-cell survival, the receptor activator of RANKL and TNF-related activation-induced cytokine (10, 11). The agreed nomenclature for this molecule is now RANKL. RANKL is expressed as a membrane-bound protein; however, this molecule can be cleaved by a specific protease to produce a soluble form that retains biological activity (12). Finally, a cognate receptor that mediates RANKL activity was identified by genomic analysis of a primary osteoclast precursor cell cDNA library (13). This molecule was shown to be identical to the receptor activator of RANK (10). RANKL has been shown to stimulate osteoclast formation in vitro, whereas, both recombinant and purified native OPG have been shown to inhibit osteoclast formation and activity. Hepatic overexpression of OPG in mice results in osteopetrosis, whereas inactivation of the OPG gene leads to osteoporosis. Furthermore, inactivation of RANKL in mice leads to osteopetrosis. These studies have highlighted the critical nature of this system in regulating normal skeletal biology. Within this system OPG plays a critical role in regulating osteoclast formation and preventing uncontrolled bone resorption.

OPG has recently been shown to bind another ligand, the TNF-related apoptosis-induced ligand (TRAIL) (14). TRAIL (Apo2L) is also a member of the TNF superfamily (1). TRAIL functions as a homotrimer and mediates its biological activity through four TRAIL receptors (15). Two of these receptors, death receptor 4 (DR4 or TRAILR1) and death receptor 5 (DR5 or TRAILR2), contain death domain motifs and promote apoptosis. In contrast, the other two receptors, DcR1, which lacks the cytoplasmic domain, and DcR2, which contains only a partial death domain, are unable to induce apoptosis and function as decoy receptors. TRAIL binding to DR4 or DR5 results in signaling through the death-inducing signaling complex and induces apoptosis in tumor cells but appears to lack activity against normal cells. Blocking TRAIL activity in vivo has been shown to promote tumor development and increase liver metastasis, and mice deficient in TRAIL have increased metastasis and tumor growth (16-19). These data suggest that one of the normal physiological roles of TRAIL is in immune surveillance. More recently, TRAIL has been shown to prevent OPG from inhibiting RANKL-induced osteoclast formation in vitro (20). Furthermore, OPG produced by tumor cells or osteoblasts is able to prevent TRAIL-induced apoptosis of tumor cells (21, 22). These data are consistent with OPG playing a pivotal role in regulating these two TNF pathways, the RANKL/RANK system and the TRAIL/TRAILR system. However, there are only limited data investigating the binding of OPG to RANKL and TRAIL, and these studies utilize non-native proteins and at non-physiological temperatures. Indeed, binding studies have suggested that the affinity of OPG for RANKL may be as much as 200 times greater than for TRAIL (23). This has been used to argue that the OPG-TRAIL interaction is of limited biological importance. However, this conclusion is not supported by data generated in complex cell-based systems in vitro (21, 22).

Thus, the nature of the binding of native OPG with RANKL and TRAIL at physiological temperature is poorly understood, and there are no data directly comparing the binding affinity of OPG for RANKL and TRAIL. Therefore, in the present study we have investigated the ability of OPG to bind to both RANKL and TRAIL and prevent association with their cognate receptors. We have also investigated the ability of TRAIL to prevent OPG from inhibiting RANKL binding RANK and determined the binding affinity of OPG for RANKL and TRAIL under physiological conditions.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Bacterial Strains and Growth Conditions—Escherichia coli strain XL1 Blue MRF: D(mcrA)183 D(mcrCB-hsdSMR-mrr)173 endA1 supE44 Thi-1 recA1 gyrA96 relA1 lac [F_proAb lacIqZDM15 Tn10 (Tetr)] (Stratagene) was used for cloning, stable propagation, and preparation of plasmid DNA. E. coli BL21 (F, ompT, hsdSB, gal, dcm), an OmpT-negative, protease-deficient strain, was used as a plasmid host for all TRAIL expression experiments (24). E. coli strains were grown in LB medium supplemented with 100 µg/ml ampicillin.

Cloning of the TRAIL Gene—IMAGE Consortium human TRAIL cDNA clone 5504670 (Geneservice Ltd., Cambridge, UK) was used as a source for cloning. The TRAIL gene was amplified by PCR using Pfu polymerase (Stratagene) (25). The forward primer carried an EcoRI restriction site and overlapped the coding sequence for amino acids 114-119. The reverse primer was designed to overlap the sequence coding for amino acids 277-281 and contained a BamHI restriction site. After amplification the PCR product was gel-purified, incubated with the appropriate restriction enzymes, and cloned into the vector pUC18 (26) under the control of the isopropyl 1-thio-beta-D-galactopyranoside-inducible lac promoter. The ligation mixture was electroporated into competent E. coli XL1BlueMRF cells, and transformants were selected for ampicillin resistance. Plasmid DNA was isolated from individual clones using the alkaline-extraction method (27) and analyzed for the presence of the TRAIL insert. The representative plasmid was designated pTRAIL1. All other general DNA manipulations were performed as previously described (28).

DNA Sequence Determination—The TRAIL insert in plasmid pTRAIL1 was sequenced using the dye termination method with an ABI Big Dye sequencing kit (Applied Biosystems). DNA sequence analysis was performed using MacVector and AssemblyLIGN (International Biotechnologies, Cambridge, UK) software packages.

TRAIL Protein Purification—Cells from an overnight 3-ml culture were used to inoculate 400 ml of LB medium. The culture was grown to an A550 nm of 0.5 (mid-log phase). TRAIL expression was induced by addition of isopropyl 1-thio-beta-D-galactopyranoside (final concentration, 0.5 mM). Incubation was continued for 3 h, and bacterial cells were pelleted by centrifugation. The bacterial cell pellet was resuspended in 50 mM Tris-HCl, pH 8, 200 mM NaCl buffer containing lysozyme, sodium deoxycholate, and phenylmethylsulfonyl fluoride (Sigma), and a crude lysate was obtained by sonification. The lysate was centrifuged to remove cell debris, and the supernatant was treated with polyethyleneimine to remove DNA. Protein was recovered by precipitation with ammonium sulfate and dialyzed against loading buffer (25 mM potassium phosphate, pH 6). The dialyzed sample was then loaded onto an SP-Sepharose cation exchange column (GE Healthcare) and eluted with a 0 to 1 M NaCl gradient. Fractions containing TRAIL protein were pooled, dialyzed against 50 mM Tris-HCl, pH 8, 200 mM NaCl buffer, and loaded onto a nickel-chelating HiTrap column (GE Healthcare). The elution was performed using a 1-250 mM linear imidazole gradient. Fractions containing TRAIL were concentrated using a VIVASPIN concentration device (Vivascience), and the protein was purified to homogeneity by gel filtration using a Superdex 200 matrix column (GE Healthcare). A Detoxi-GelTM AffinityPakTM Pre-packed Column (Pierce) was used to remove bacterial endotoxin.

Protein Electrophoresis and Western Blot Analysis—Protein fractions were subjected to SDS-PAGE (29) using a 12% polyacrylamide separating gel and blotted onto BioTraceTM PVDF membrane (PALL Life Sciences) using a Trans-blot SD semidry transfer cell (Bio-Rad) according to the manufacturer's instructions. After staining and drying, the excised bands were used for N-terminal amino acid sequencing. Unstained membrane was probed by Western blot analysis using an anti-TRAIL antibody (R&D Systems) and detected with a peroxidase-conjugated rabbit anti-mouse antibody (DAKO) and o-phenylenediamine dihydrochloride as a substrate (Sigma).

N-terminal Protein Sequence Determination and MALDI-TOF Analysis—N-terminal sequence was determined by Dr. J. N. Keen in the BioMolecular Analysis Facility, School of Biochemistry and Molecular Biology, University of Leeds, UK. MALDI-TOF analysis was performed by the Aberdeen Protein Facility, Department of Medical Sciences, Aberdeen University, UK.

Assessment of TRAIL Bioactivity—TRAIL bioactivity was assessed on the human myeloma cell line RPMI-8226 using a colorimetric cytotoxicity assay (30). Briefly, serial 2-fold dilutions of TRAIL (200-50 ng/ml in 50 µl), prepared in RPMI 1640 culture media, were added to the wells of a 96-well tissue culture plate. RPMI-8226 human myeloma cells (50 µl of 105/ml) were added, and the mixture was incubated for 24 h at 37 °C. 20 µl of CellTiter96® AQueous One Solution Reagent containing 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and phenazine ethosulfate (PES) (Promega, Madison, WI) were added to each well. Absorbance at 490 nm was measured after 2 h. Wells containing cells only in the absence of TRAIL and wells containing medium only were used as controls. The ability of TRAIL to induce apoptosis of RPMI-8226 cells was determined by assessing changes in nuclear morphology and using a fluorescence in situ nick translation assay as described previously (22).

Assessment of OPG-RANKL and OPG-TRAIL Interactions Using a Solid-phase Assay—Measurement of the direct interaction between the RANK, RANKL, OPG, and TRAIL proteins was performed using a modified enzyme-linked immunosorbent assay technique. The capacity of OPG to directly inhibit RANKL binding to RANK was investigated using the following approach. RANK (R&D Systems), 50 ng in 0.1 ml of carbonate/bicarbonate coating buffer (pH 9.0), was bound to 96-well microtiter plates (Immulon 2, Dynex) by incubation overnight at 37 °C. Wells were washed with washing buffer (0.005% Tween 20 in phosphate-buffered saline) and blocked for 2 h with 2% skimmed milk in phosphate-buffered saline. Plates were incubated with 0.1 ml of buffer containing 25 ng/ml RANKL (R&D Systems) and increasing concentration of OPG (R&D Systems, range 25-800 ng). Control wells contained RANKL protein only. For comparison, wells containing a constant concentration of RANKL and an increasing concentration of RANK protein (range 25-800 ng per well) were prepared. RANKL bound to RANK was detected with an anti-RANKL antibody (diluted 1:500; 0.1 ml per well) and incubated for 2 h at 37 °C. After washing, the plate was incubated with a secondary antibody (peroxidase-conjugated rabbit anti-mouse antibody diluted 1:500, 0.1 ml per well, DAKO). Wells were incubated with the chromogenic substrate o-phenylenediamine dihydrochloride (Sigma), and color was measured at 490 nm.

In separate experiments, the capacity of OPG to inhibit TRAIL binding to its receptor R1 was investigated using an identical approach. TRAILR1 (R&D Systems), 50 ng in 0.1 ml of carbonate/bicarbonate buffer, was bound to a microtiter plate. After washing and blocking, wells were incubated with a fixed concentration of TRAIL (0.1 ml of 25 ng/ml) and increasing concentrations of OPG or soluble TRAILR1 (range 25-800 ng per well). The concentration of bound TRAIL was assessed using an anti-TRAIL antibody (R&D Systems).

The potential of TRAIL to inhibit OPG from binding to RANKL was investigated using an identical protocol. RANK (50 ng in 0.1 ml) was bound to wells and incubated with a fixed concentration of RANKL and OPG (25 ng each per well) and variable concentrations of TRAIL (range 25-800 ng per well). RANKL bound to RANK was detected with an anti-RANKL antibody. All assays were performed in triplicate.

Plasmon Surface Resonance Analysis of OPG-RANKL and OPG-TRAIL Interactions—The affinity of OPG for RANKL and TRAIL was determined using a BIAcore 2000 optical biosensor (BIAcore AB) and a resonance equilibrium method (31). A streptavidin sensor chip, SA5, was conditioned with 1 M NaCl, 50 mM NaOH. Biotinylated anti-OPG antibody (R&D Systems) was injected over the flow cell until the response reached 1000 response units. OPG (100 nM) was injected at a flow rate of 5 µl/min until 500 response units were immobilized. Increasing concentrations of RANKL or TRAIL (range 1-200 mM) were injected at 5 µl/min for 4 min, and the responses were recorded. The chip surface was regenerated to baseline after each cycle with 5 mM HCl. The resonance signal measured on the reference cell (containing anti-OPG antibody only) was subtracted from the signal measured on the experimental flow cell. All experiments were performed at 20 °C and 37 °C, and all sensograms were corrected for buffer injection. Results were fitted into 1 to 1 binding model using BIAevaluation software 3.1 (BIAcore AB), and equilibrium dissociation constants (KD) were calculated.

Assessing the Ability of TRAIL to Block OPG-induced Inhibition of Osteoclast Formation—Mouse mononuclear cells were isolated from whole blood using Histopaque-1077 (Sigma) and seeded onto glass coverslips in a 96-well plate at a density of 1 x 105 per well in {alpha}-minimal essential medium (Invitrogen) containing 10% fetal calf serum. After 2 h the coverslips were washed and further incubated in medium (0.2 ml per well) containing macrophage colony-stimulating factor (25 ng/ml, R&D Systems), and recombinant human RANKL (30 ng/ml) in the presence or absence of OPG (50 ng/ml) or OPG in combination with TRAIL (500 ng/ml). The cells were incubated for 7 days at 37 °C, and osteoclasts were stained for tartrate-resistant acid phosphatase (TRAP) activity using an acid phosphatase kit (Sigma). The number of TRAP-positive multinuclear osteoclasts was counted under light microscopy.

Statistical Analysis—All data are represented as mean ± S.E. Concentration response relationships were analyzed by analysis of variance with a Scheffe post hoc test.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Soluble Extracellular Domain of the TRAIL Protein, Expressed in E. coli, Is Biologically Active—An high fidelity PCR-amplified extracellular segment of the TRAIL gene was cloned into a pUC18-based vector under the control of inducible lac promoter. After induction, the bacterial pellet was successfully processed to obtain protein. Following cell lysis, insoluble particles and DNA were removed, and the cell lysate was subjected to cation exchange, affinity, and gel-filtration chromatography to obtain pure soluble TRAIL (Fig. 1A). Western blot analysis confirmed that the purified protein reacted with a specific anti-TRAIL antibody (Fig. 1B). The authenticity of the protein was confirmed by N-terminal amino acid analysis, which showed the sequence Val-Arg-Glu-Arg-Gly-Pro-Gln, and was confirmed to be identical to the published sequence. MALDI-TOF analysis further confirmed the expressed protein to be TRAIL. Biological activity was assessed by measuring the cytotoxic activity of purified TRAIL on the human myeloma cell line RPMI-8226. Increasing concentrations of TRAIL were shown to reduce cell viability (Fig. 2A). At concentrations of 50-100 ng/ml TRAIL cell viability was reduced by >90%. To confirm that the reduction in viability is a consequence of increasing apoptosis, RPMI-8226 cells were treated with TRAIL, and nuclei were examined following staining with 4',6-diamidino-2-phenylindole. Nuclei were shown to have condensed chromatin and the presence of apoptotic bodies, both features consistent with apoptosis (Fig. 2B). The in situ nick translation assay confirmed that the TRAIL protein promoted an increase in tumor cell apoptosis (Fig. 2, C and D).


Figure 1
View larger version (73K):
[in this window]
[in a new window]

  		FIGURE 1.
Expression and purification of recombinant human TRAIL protein. A, TRAIL was cloned and expressed using the bacterial expression system outlined under "Experimental Procedures" and purified by a series of chromatography steps. M, molecular mass protein standards (size in kilodaltons is shown); 1, un-induced culture; 2, induced culture; 3, cell lysate after cation chromatography; 4, following Ni2+-affinity chromatography; 5, following gel filtration. The arrow indicates the position of TRAIL protein. B, Western blot analysis of purified protein (PP) demonstrated immunoreactivity with an anti-TRAIL antibody (arrowed). The authenticity of the pure protein was confirmed by N-terminal amino acid sequencing and MALDI-TOF analysis.

 


Figure 2
View larger version (29K):
[in this window]
[in a new window]

  		FIGURE 2.
Cloned TRAIL is biologically active. Recombinant human TRAIL expressed in E. coli reduces cell viability and induces apoptosis in the human myeloma cell line RPMI-8226. A, reduction in cell viability following treatment with purified TRAIL as measured using the MTS-based chromogenic cytotoxic assay. B, apoptotic cell death was apparent upon treatment of RMPI-8226 cells with purified TRAIL. Cell nuclei were stained with 4',6-diamidino-2-phenylindole and examined by fluorescence microscopy; original magnification, 40x. Apoptotic nuclei are arrowed. C, apoptosis was assessed using the fluorescence nick translation assay. TRAIL was shown to increase fluorescently label cells (arrowed). D, the effect of increasing concentrations on the proportion of the apoptotic cells as determined using the fluorescence nick translation assay. Con = recombinant TRAIL expressed in mammalian cells (R&D Systems). For details see "Experimental Procedures."

 
OPG Prevents TRAIL Binding TRAIL Receptor R1 and RANKL Binding Cognate Receptor RANK—A competitive enzyme-linked immunosorbent assay technique was developed to measure the effect of OPG on TRAIL-TRAILR1 binding. TRAIL receptor was bound to a microtiter plate and incubated with a fixed amount of TRAIL and increasing concentrations of OPG or soluble TRAILR1. An anti-TRAIL antibody was used to establish the amount of bound TRAIL. Soluble TRAILRI inhibited TRAIL from binding immobilized receptor in a concentration-dependent manner (p < 0.001, Fig. 3A). OPG was also able to dose-dependently inhibit TRAIL from binding to the TRAILR1 at 37 °C (p < 0.005), suggesting that OPG could partially compete with the TRAILR1 for TRAIL (Fig. 3B). The magnitude of inhibition was reduced when compared with soluble TRAILR1; however, inhibition was still seen at concentrations of 25 ng/ml and higher.

In parallel experiments the ability of OPG to prevent the RANK-RANKL interaction was investigated. Microtiter plate wells were coated with RANK and incubated with a fixed amount of RANKL and increasing concentrations of soluble RANK or OPG. Soluble RANK prevented RANKL binding-immobilized RANK in a concentration-dependent manner (p < 0.001, Fig. 4A). OPG also dose-dependently inhibited RANKL from binding RANK (p < 0.001, Fig. 4B). The level of inhibition was similar for sRANK and OPG, which is consistent with the two proteins having a similar affinity for RANKL.

Because OPG was shown to bind TRAIL, we also investigated whether TRAIL could prevent OPG from inhibiting RANKL binding to RANK. Microtiter plates coated with RANK were incubated with a fixed amount of RANKL and OPG and increasing concentrations of TRAIL. TRAIL dose-dependently prevented OPG from blocking RANKL-RANK binding (p < 0.001, Fig. 5). TRAIL was shown not to bind RANK directly (data not shown). This reversal of the potential of OPG to inhibit RANKL-RANK binding is a direct consequence of the capacity of TRAIL to bind OPG.

OPG Has a Similar Affinity for TRAIL as RANKL at Physiological Temperature—Quantitative measurement of OPG-TRAIL and OPG-RANKL binding was performed by BIAcore analysis. OPG was captured on a streptavidin-coated chip via a biotinylated anti-OPG antibody. Increasing concentrations of TRAIL or RANKL were injected over the chip surface, and the response was recorded in the form of a sensogram (Fig. 6). The steady-state response, in response units, was obtained for each analyte concentration, and data were fitted to the Hill equation to generate an equilibrium dissociation constant. The binding affinity of OPG for TRAIL at 37 °C was 45 nM, whereas the affinity for RANKL was 23 nM. The influence of temperature and molecular structure of interacting proteins were also examined. Binding experiments were performed at both 20 °C and 37 °C. Two forms of OPG protein, native OPG and OPG, fused to the Fc fragment of the human heavy chain were also used as capturing ligands. Two forms of TRAIL were also examined, the first produced in E. coli as a non-glycosylated form (detailed above) and the second produced in mammalian cells as glycosylated protein (R&D Systems). Temperature had little effect on OPG binding TRAIL. Equally the two forms of OPG had a limited effect on binding TRAIL (Fig. 6C). In contrast, temperature did affect OPG binding RANKL. The binding affinity of OPG for RANKL was lower at 20 °C than at 37 °C. Furthermore, the native OPG had a lower affinity for RANKL than the OPG-Fc form of the protein (Fig. 6C).


Figure 3
View larger version (21K):
[in this window]
[in a new window]

  		FIGURE 3.
OPG prevents TRAIL binding TRAIL receptor R1. Microtiter plates containing bound TRAIL receptor R1 were incubated with samples containing a constant amount of TRAIL (25 ng) and increasing amounts of TRAILR1 (A) or OPG (B). After washing, the plates were incubated with biotinylated anti-TRAIL antibody, and bound antibody was visualized with avidin-conjugated horseradish peroxidase and the chromogenic substrate, o-phenylenediamine dihydrochloride. The amount of bound TRAIL in individual wells is expressed as a percentage of the TRAIL bound in control wells in the absence of OPG or TRAILR1 (100%). *, p < 0.05 when compared with control.

 


Figure 4
View larger version (21K):
[in this window]
[in a new window]

  		FIGURE 4.
OPG prevents RANKL binding of the receptor RANK. Microtiter plates containing bound RANK were incubated with samples containing a constant amount of RANKL (25 ng) and increasing amounts of RANK (A) or OPG (B). After washing, the plates were incubated with biotinylated anti-RANKL antibody and visualized with avidin-conjugated horseradish peroxidase and the chromogenic substrate, o-phenylenediamine dihydrochloride. The amount of bound RANKL in individual wells is expressed as a percentage of the RANKL bound in control wells in the absence of OPG or RANK (100%). *, p < 0.001 when compared with control.

 
OPG Prevents TRAIL-induced Apoptosis, and TRAIL Prevents OPG Inhibition of Osteoclast Formation in Vitro—To determine the consequences of the TRAIL-OPG interaction we performed two different in vitro assays. The potential of OPG to inhibit TRAIL-mediated apoptosis of the human myeloma cell line RPMI8226 was performed using an MTS-based cytotoxic assay. Increasing concentrations of TRAIL reduced cell viability (Fig. 7A). This was reversed by incubating with increasing concentrations of OPG (Fig. 7).

To determine whether TRAIL could prevent the OPG-induced inhibition of RANKL-regulated osteoclast formation, we assessed its effects on murine osteoclastogenesis. RANKL and macrophage colony-stimulating factor induced the formation of TRAP-positive multinucleated osteoclasts (Fig. 7B) with capacity to resorb mineralized substrates (data not shown). OPG prevented RANKL-induced osteoclast formation (Fig. 7, B and C). However, TRAIL blocked the OPG-induced inhibition of osteoclast formation (Fig. 7C).


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
In the present study we have investigated the nature of the binding of OPG with two ligands, RANKL and TRAIL. An important pre-requisite in our approach was to use native proteins devoid of any additional modifications, which could influence their binding properties and lead to inaccurate conclusions regarding the precise physiological role of individual receptor-ligand interactions. To achieve this we expressed an extracellular form of TRAIL (amino acids 114-281 only) in E. coli. The authenticity of the TRAIL protein was confirmed by Western blot analysis with a TRAIL-specific antibody, N-terminal amino acid sequencing, and MALDI-TOF analysis. Treatment of the human myeloma cell line, RPMI-8226 cells, with the TRAIL protein demonstrated a significant reduction in cell viability. This was comparable to a reduction in viability seen with a recombinant form of soluble TRAIL expressed in mammalian cells. The decrease in viability was associated with changes in nuclear morphology, including condensed chromatin and the formation of apoptotic bodies, consistent with apoptosis. Induction of apoptosis by the TRAIL protein was also seen using an in situ nick translation assay. These data confirm that this form of TRAIL retained appropriate biological activity.


Figure 5
View larger version (20K):
[in this window]
[in a new window]

  		FIGURE 5.
TRAIL reverses the potential of OPG to inhibit RANKL binding to RANK. Microtiter plates containing bound RANK were incubated with a constant amount of RANKL and OPG (25 ng each) and an increasing amount of TRAIL. After washing, the plate was incubated with biotinylated anti-RANKL antibody and visualized with avidin-conjugated horseradish peroxidase and the chromogenic substrate, o-phenylenediamine dihydrochloride. The amount of bound RANKL in individual wells is expressed as a percentage of the RANKL bound in control wells in the absence of TRAIL (100%). *, p < 0.001 when compared with control.

 


Figure 6
View larger version (13K):
[in this window]
[in a new window]

  		FIGURE 6.
OPG has a similar affinity for TRAIL and RANKL at 37 °C. Human OPG or OPG-Fc was captured onto a streptavidin-coated SA chip via a biotinylated anti-OPG antibody, and increasing concentrations of TRAIL or RANKL protein were passed over. The change in surface plasmon resonance as a consequence of binding to immobilized OPG was recorded in the form of a sensogram (A). An example overlay plot of sensograms showing (from bottom to top) increasing concentrations of TRAIL (1, 10, 20 (twice), 40, 80, and 150 nM) passed over immobilized OPG. Only the regions used in determining equilibrium dissociation constants are shown. B, the equilibrium dissociation constant KD was calculated by curve fitting to data points generated from the sensograms (C). Equilibrium dissociation constants for OPG and OPG-Fc binding to RANKL, TRAIL in bacteria, and TRAIL expressed in mammalian cells (TRAIL (Glyc)) at 20 °C and 37 °C are shown.

 
The induction of apoptosis is consistent with previous reports demonstrating that different forms of TRAIL protein can induce apoptosis in a range of cell types. A FLAG-tagged extracellular domain of TRAIL protein (amino acids95-281) was reported to have limited activity, although oligomerization with an anti-FLAG antibody enhanced biological activity (32). Furthermore, a polyhistidine-tagged soluble form (amino acids 114-281) was demonstrated to be functional but was cytotoxic to human hepatocytes (33, 34). However, this form of TRAIL was shown to contain a substantial fraction of dimers and trimers of a non-naturally polymerized protein characterized by the existence of intermolecular disulfide bonds (35). Importantly, it is the FLAG-tagged and biotin-tagged TRAIL proteins that have previously been used for the measurement of binding affinity of TRAIL for OPG (14, 23). A similar form of TRAIL to that expressed in the present study (amino acids 114-281) was shown to be fully active (36, 37). Subsequently, it has been shown that this form of protein undergoes appropriate polymerization to form biologically active homotrimers containing an internal zinc atom. This supports the suggestion that native TRAIL devoid of additional modifications is more appropriate for binding studies than tagged variants.

In the present study, using a solid-phase assay, we demonstrated that OPG prevents RANKL from binding to RANK. In a similar experimental system OPG was shown to prevent TRAIL from binding the TRAILR1. We also demonstrated that TRAIL has the capacity to reverse the inhibitory action of OPG on RANKL-RANK binding by interacting with OPG. TRAIL, when present in excess over OPG, directly enhanced the binding of RANKL to its receptor RANK by titrating out the inhibitory molecule. This contrasts with a previous report demonstrating that OPG could not inhibit TRAIL-TRAILR1 binding (23). The reason for the difference between the two studies is unclear but may be explained by the nature of the proteins used to demonstrate inhibition of binding. In the previous study an OPG-Fc construct and a biotin-tagged form of TRAIL were used (23), whereas, in the present study, proteins devoid of these additions were used. These protein modifications could mask the relevant epitopes involved in recognition of binding, therefore preventing interaction. Alternatively, they could introduce conformational constrains, which may affect the position and availability of the reacting epitopes for binding.


Figure 7
View larger version (33K):
[in this window]
[in a new window]

  		FIGURE 7.
OPG prevents TRAIL-mediated reductions in cell viability, and TRAIL reverses the ability of OPG to inhibit osteoclastogenesis. A, human myeloma RPMI8226 cells were incubated with increasing amounts of TRAIL alone (hatched columns) or in combination with OPG (black columns). Cell viability was measured using the MTS cytotoxic assay. Data are expressed as a percentage of control in the absence of TRAIL or OPG (white column). B, mouse peripheral blood monocytes were incubated in the presence of RANKL and macrophage colony-stimulating factor to induce osteoclastogenesis. Cultures were incubated (i) without OPG, (ii) with OPG, and (iii) with OPG + TRAIL. Osteoclasts are identified following TRAP staining as TRAP-positive multinucleated cells (arrowed). C, the relative number of TRAP-positive multinucleated osteoclasts is illustrated.

 
Having established that OPG could bind both RANKL and TRAIL and compete for their respective receptors, we determined the binding affinity of OPG for RANKL and TRAIL, using a surface plasmon resonance technique. OPG was bound to a biotinylated sensor chip via a specific OPG antibody. This approach has previously been shown to retain flexibility of the immobilized molecule, more accurately reflecting physiological conditions (38). At 37 °C we demonstrate that OPG has a binding affinity of 23 nM for RANKL. Although this is in the same order as the affinity reported previously (from 1.7 nM to 10 nM (8, 39, 40)) the value in the present study was higher. The reason for this is unclear but may reflect differences in the mechanisms used to couple molecules to the sensor chip. Equally in the present study affinity was determined at 37 °C. In contrast, in previous studies affinity was determined at 25 °C. In the present study we demonstrated that temperature influenced affinity, with lower temperatures being associated with reduced affinity. We also demonstrated that OPG binds to native TRAIL with an affinity of 45 nM. This is of a similar order of magnitude to OPG binding RANKL and is consistent with data obtained using the competitive solid-phase assays. However, these data contrast with previous studies that have reported binding affinities ranging from 3 nM to 400 nM (14, 23). The reason for the broad range and the differences between studies is unclear. Emery et al. (14) reported the affinity of OPG-TRAIL complex to be 3 nM using plasmon surface resonance measurement. However, affinity was determined at 25 °C using modified forms of proteins (OPG-Fc and TRAIL-FLAG). Although we have demonstrated that temperature has a limited effect on OPG binding to TRAIL, it is possible that the FLAG tag will influence binding. An affinity constant of 400 nM for OPG-Fc binding TRAIL-biotin has been reported. However, this study used isothermal titration calorimetry rather than BIAcore analysis and modified proteins (23).

In the present study the data were all generated at physiological temperature using native proteins, and within the same experiment, allowing direct comparison. The data demonstrate that OPG has a similar affinity for RANKL and TRAIL. This is entirely consistent with the data generated using the solid-phase assay and that has been reported in more complex in vitro culture conditions (21, 22, 41). The mechanism responsible for the OPG binding RANKL and TRAIL is unclear. Although the crystal structures of RANKL and TRAIL have been solved, there is no published structure for OPG. However, modeling studies have allowed OPG peptidomimetics to be designed (42). These peptides have been shown to block RANKL activity in a functional osteoclast assay but not the ability of TRAIL to induce tumor cell apoptosis (43). This is in contrast to native OPG, which is able to inhibit both processes. The solid-phase assays used in the present studies did demonstrate that OPG was less effective at preventing TRAIL binding TRAILR1, than RANKL binding RANK. However, equilibrium dissociation constants were similar. This suggests that OPG can bind both RANKL and TRAIL, but there are different structural determinants of binding. In the former case OPG may be able to completely prevent RANKL binding RANK, whereas OPG may only be partly able to inhibit binding of TRAIL to TRAILR1.


Figure 8
View larger version (25K):
[in this window]
[in a new window]

  		FIGURE 8.
Diagrammatic representation of the central role that OPG plays in regulating the RANKL-RANK and TRAIL-TRAILR1 pathways.

 
Finally, we demonstrated the potential importance of the OPG-TRAIL interaction using live cells and tissue culture-based assays. OPG was able to prevent TRAIL-mediated reductions in cell viability, confirming our previous reports (21, 22). Furthermore, the opposite was also observed in that TRAIL was shown to prevent OPG inhibition of RANKL-induced osteoclastogenesis.

These data are likely to have important biological consequences, because it places OPG in a key position to regulate the function of these two important signaling pathways (Fig. 8). OPG clearly plays a critical role in regulating osteoclastic bone resorption. However, the present data strongly suggest that OPG will also play an important role in regulating TRAIL biology. Because TRAIL has been shown to play an important role in immunosurveillance, it is likely that OPG may also regulate this activity. This may be particularly important in tissues in which OPG is highly expressed, for example in bone. In particular this may have implications for tumors that colonize bone such as multiple myeloma, breast, or prostate cancer metastasis. The importance of OPG in regulating these different pathways in these locations is likely to be dependent upon the relative concentrations of the different components of the pathways, their location, and the timing of expression of these molecules.


   FOOTNOTES
 
* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 To whom correspondence should be addressed: Tel.: 44-114-271-2414; Fax: 44-114-271-1711; E-mail: p.croucher{at}sheffield.ac.uk.

2 The abbreviations used are: TNF, tumor-necrosis factor; RANKL, receptor activator of NF-{kappa}B; TRAIL, TNF-related apoptosis-inducing ligand; OPG, osteoprotegerin; DR4 and -5, death receptors 4 and 5; MALDI-TOF, matrix-assisted laser desorption ionization time-of-flight; TRAP, tartrate-resistant acid phosphatase; TRAILR1, TRAIL receptor 1. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Bodmer, J.-L., Schneider, P., and Tschopp, J. (2002) Trends Biochem. Sci. 27, 19-26[CrossRef][Medline] [Order article via Infotrieve]
  2. Blair, J. M., Zhou, H., Siebel, M. J., and Dunstan, C. R. (2006) Nat. Clin. Pract. Oncol. 3, 41-49[CrossRef][Medline] [Order article via Infotrieve]
  3. Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Luthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M., Elliott, R., Colombero, A., Tan, H.-L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T. M., Hill, D., Pattison, W., Campbell, P., Sander, S., Van, G., Tarpley, J., Derby, P., Lee, R., and Boyle, W. J. (1997) Cell 89, 309-319[CrossRef][Medline] [Order article via Infotrieve]
  4. Tsuda, E., Goto, M., Mochizuki, S., Yano, K., Kobayashi, F., Morinaga, T., and Higashio, K. (1997) Biochem. Biophys. Res. Commun. 234, 137-142[CrossRef][Medline] [Order article via Infotrieve]
  5. Kwon, B. S., Wang, S. A., Udagawa, N., Haridas, V., Lee, Z. H., Kim, K. K., Oh, K.-O., Greene, J., Li, Y., Su, J., Gentz, R., Aggarwal, B. B., and Ni, J. (1998) FASEB J. 12, 845-854[Abstract/Free Full Text]
  6. Yamaguchi, K., Kinosaki, M., Goto, M., Kobayashi, F., Tsuda, E., Morinaga, T., and Higashio, K. (1998) J. Biol. Chem. 273, 5117-5123[Abstract/Free Full Text]
  7. Tomoyashy, A., Goto, M., Fujise, N., Mochizuki, S., Yasuda, H., Morinaga, T., Tsuda, E., and Higashio, K. (1998) Biochem. Biophys. Res. Commun. 245, 382-387[CrossRef][Medline] [Order article via Infotrieve]
  8. Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliot, R., Colombero, A., Elliot, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y.-X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J., and Boyle, W. J. (1998) Cell 93, 165-176[CrossRef][Medline] [Order article via Infotrieve]
  9. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Moinaga, T., Higashio, K., Udagawa, N., Takahashi, N., and Suda, T. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 3597-4602[Abstract/Free Full Text]
  10. Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M., DuBose, R. F., Cosman, D., and Galibert, L. (1997) Nature 390, 175-179[CrossRef][Medline] [Order article via Infotrieve]
  11. Wong, B. R., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalachikov, S., Cayani, E., Barlet, F. S., III, Frankel, W. N., Lee, S. Y., and Choi, Y. (1997) J. Biol. Chem. 272, 25190-25194[Abstract/Free Full Text]
  12. Lum, L., Wong, B. R., Josien, R., Becherer, J. D., Erdjument-Bromage, H., Schlondorff, J., Tempst, P., Choi, Y., and Blobel, C. P. (1999) J. Biol. Chem. 274, 13613-13618[Abstract/Free Full Text]
  13. Hsu, H., Lacey, D., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliot, G., Kelley, M. J., Sarosi, I., Wang, L., Xia, X.-Z., Elliot, R., Chiu, L., Black, T., Scully, S., Capparelli, C., Morony, S., Shimamoto, G., Bass, M., and Boyle, W. J. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 3540-3545[Abstract/Free Full Text]
  14. Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., Dodds, R. A., James, I. E., Rosenberg, M., Lee, J. C., and Young, P. R. (1998) J. Biol. Chem. 273, 14363-14367[Abstract/Free Full Text]
  15. LeBlanc, H. N., and Ashkenazi, A. (2003) Cell Death Differ. 10, 66-75[CrossRef][Medline] [Order article via Infotrieve]
  16. Takeda, K., Hayakawa, Y., Smyth, M. J., Kayagaki, N., Yamaguchi, N., Kakuta, S., Iwakura, Y., Yagita, H., and Okumura, K. (1991) Nat. Med. 7, 94-100[CrossRef]
  17. Takeda, K., Smyth, M. J., Cretney, E., Hayakawa, Y., Kayagaki, N., Yagita, H., and Okamura, K. (2002) J. Exp. Med. 195, 161-169[Abstract/Free Full Text]
  18. Cretney, E., Takeda, K., Yagita, H., Glaccum, M., Peschon, J. J., and Smyth, M. J. (2002) J. Immunol. 168, 1356-1361[Abstract/Free Full Text]
  19. Zerafa, N., Westwood, J. A., Cretney, E., Mitchell, M., Waring, P., Iezzi, M., and Smyth, M. J. (2005) J. Immunol. 175, 5586-5590[Abstract/Free Full Text]
  20. Zauli, G., Rimondi, E., Nicolin, V., Melloni, E., Celeghini, C., and Secchiero, P. (2004) Blood 104, 2044-2050[Abstract/Free Full Text]
  21. Holen, I., Croucher, P. I., Hamdy, F. C., and Eaton, C. L. (2002) Cancer Res. 62, 1619-1623[Abstract/Free Full Text]
  22. Shipman, C. M., and Croucher, P. I. (2003) Cancer Res. 63, 912-916[Abstract/Free Full Text]
  23. Truneh, A., Sharma, S., Silvermn, C., Khandekar, S., Reddy, M. P., Deen, K. C., Mclaughlin, M. M., Srinivasula, S. M., Livi, G. P., Marshall, L. A., Alnemri, E. S., Williams, W. V., and Doyle, M. L. (2000) J. Biol. Chem. 275, 23319-23325[Abstract/Free Full Text]
  24. Studier, F. W., and Moffatt, B. A. (1986) J. Mol. Biol. 189, 113-130[CrossRef][Medline] [Order article via Infotrieve]
  25. Lundberg, K. S., Shoemaker, D. D., Adams, M. W., Short, J. M., Sorge, J. A., and Mathur, E. J. (1991) Gene (Amst.) 108, 1-6[CrossRef][Medline] [Order article via Infotrieve]
  26. Yanisch-Perron, C., Vieira, J., and Messing, J. (1985) Gene (Amst.) 33, 103-119[CrossRef][Medline] [Order article via Infotrieve]
  27. Birnboim, H. C., and Doly, J. (1979) Nucleic Acids Res. 7, 1513-1523[Abstract/Free Full Text]
  28. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
  29. Laemmli, U. K. (1970) Nature 227, 680-685[CrossRef][Medline] [Order article via Infotrieve]
  30. Schneider, P., Holler, N., Bodmer, J.-L., Hahne, M., Frei, K., Fontana, A., and Tschopp, J. (1998) J. Exp. Med. 187, 1205-1213[Abstract/Free Full Text]
  31. Karlsson, R., Michelsson, A., and Mattsson, L. (1991) J. Immunol. Methods 145, 229-240[CrossRef][Medline] [Order article via Infotrieve]
  32. Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., and Goodwin, R. G. (1995) Immunity 3, 673-682[CrossRef][Medline] [Order article via Infotrieve]
  33. Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., and Ashkenazi, A. (1996) J. Biol. Chem. 271, 12687-12690[Abstract/Free Full Text]
  34. Jo, M., Kim, T.-H., Seol, D.-W., Esplen, J. E., Dorko, K., Billiar, T. R., and Strom, S. C. (2000) Nat. Med. 6, 564-567[CrossRef][Medline] [Order article via Infotrieve]
  35. Lawrence, D., Shahrokh, Z., Marsters, S., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., Hooley, J., Sherwood, S., Pai, R., Leung, S., Khan, L., Gliniak, B., Bussiere, J., Smith, C. A., Strom, S. S., Kelley, S., Fox, J. A., Thomas, D., and Ashkenazi, A. (2001) Nat. Med. 7, 383-385[CrossRef][Medline] [Order article via Infotrieve]
  36. Askenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Masters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Herbert, A., DeForge, L., Kuomenis, I. L., Lewis, D., Harris, L., Bussiere, J., Koeppen, H., Shahrokh, Z., and Schwall, R. H. (1999) J. Clin. Invest. 104, 155-162[Medline] [Order article via Infotrieve]
  37. Cha, S.-S., Shin, H.-C., Choi, K. Y., and Oh, B.-H. (1999) Acta Crystallogr. Sect. D Biol. Crystallogr. 55, 1101-1104[CrossRef][Medline] [Order article via Infotrieve]
  38. Myszka, D. G. (1997) Curr. Opin. Biotechnol. 8, 50-57[CrossRef][Medline] [Order article via Infotrieve]
  39. Willard, D., Chen, W.-J., Barrett, G., Blackburn, K., Bynum, J., Consler, T., Hoffman, C., Horne, E., Iannone, M. A., Kadwell, S., Parham, J., and Ellis, B. (2000) Protein Expression Purif. 20, 48-57[CrossRef][Medline] [Order article via Infotrieve]
  40. Schneeweis, L. A., Willard, D., and Milla, M. E. (2005) J. Biol. Chem. 280, 41155-41164[Abstract/Free Full Text]
  41. Nyambo, R., Cross, N., Lippitt, J., Holen, I., Bryden, G., Hamdy, F. C., and Eaton, C. L. (2004) J. Bone Mineral Res. 19, 1712-1721[CrossRef][Medline] [Order article via Infotrieve]
  42. Cheng, X., Kinosaki, M., Takami, M., Choi, Y., Zhang, H., and Murali, R. (2004) J. Biol. Chem. 279, 8269-8277[Abstract/Free Full Text]
  43. Heath, D. J., Vanderkerken, K., Cheng, X., Gallager, O., Prideaux, M., Murali, R., and Croucher, P. I. (2007) Cancer Res. 67, 202-208[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. Labrinidis, P. Diamond, S. Martin, S. Hay, V. Liapis, I. Zinonos, N. A. Sims, G. J. Atkins, C. Vincent, V. Ponomarev, et al.
Apo2L/TRAIL Inhibits Tumor Growth and Bone Destruction in a Murine Model of Multiple Myeloma
Clin. Cancer Res., March 15, 2009; 15(6): 1998 - 2009.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Lamoureux, G. Picarda, L. Garrigue-Antar, M. Baud'huin, V. Trichet, A. Vidal, E. Miot-Noirault, B. Pitard, D. Heymann, and F. Redini
Glycosaminoglycans as Potential Regulators of Osteoprotegerin Therapeutic Activity in Osteosarcoma
Cancer Res., January 15, 2009; 69(2): 526 - 536.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Labrinidis, V. Liapis, L. M. Thai, G. J. Atkins, C. Vincent, S. Hay, N. A. Sims, A. C. W. Zannettino, D. M. Findlay, and A. Evdokiou
Does Apo2L/TRAIL play any physiologic role in osteoclastogenesis?
Blood, June 1, 2008; 111(11): 5411 - 5412.
[Full Text] [PDF]

Home page
 BloodHome page
G. Zauli and P. Secchiero
Role of TRAIL in osteoclastogenesis
Blood, June 1, 2008; 111(11): 5413 - 5413.
[Full Text] [PDF]

Home page
 BloodHome page
P. Secchiero, F. Corallini, E. Rimondi, C. Chiaruttini, M. G. di Iasio, A. Rustighi, G. Del Sal, and G. Zauli
Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells
Blood, February 1, 2008; 111(3): 1287 - 1294.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/43/31601    most recent
M706078200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vitovski, S.
Right arrow Articles by Croucher, P. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vitovski, S.
Right arrow Articles by Croucher, P. I.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement